Itamar Raz
#128,495
Most Influential Person Now
Researcher
Itamar Raz's AcademicInfluence.com Rankings
Itamar Razbiology Degrees
Biology
#8300
World Rank
#11353
Historical Rank
Genetics
#823
World Rank
#915
Historical Rank
Molecular Biology
#1041
World Rank
#1065
Historical Rank
Biochemistry
#1197
World Rank
#1316
Historical Rank

Download Badge
Biology
Itamar Raz's Degrees
- Bachelors Biology Tel Aviv University
- Masters Biochemistry Tel Aviv University
Similar Degrees You Can Earn
Why Is Itamar Raz Influential?
(Suggest an Edit or Addition)Itamar Raz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. (2001) (5564)
- Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. (2013) (3012)
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (2019) (2285)
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). (2006) (1767)
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2019) (1687)
- Type 2 diabetes mellitus (2015) (1613)
- Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. (1990) (741)
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus (2006) (628)
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial (2014) (564)
- Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy (2006) (488)
- β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial (2001) (485)
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. (2019) (424)
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials (2019) (415)
- Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy (2003) (404)
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. (2019) (386)
- Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial (2009) (343)
- Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. (2005) (332)
- Insulin resistance associated with lower rates of weight gain in Pima Indians. (1991) (332)
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum (2017) (314)
- Hyperglycemia and Cardiovascular Disease in Type 2 Diabetes Mellitus: Evidence-based Approach to Primary and Secondary Prevention (2003) (265)
- Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. (1990) (222)
- Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. (2001) (217)
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial (2016) (212)
- Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. (2004) (211)
- Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage (2005) (198)
- Pre‐clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients (1996) (196)
- Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. (2007) (192)
- Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. (2019) (192)
- The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily (2013) (171)
- Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors’ Expert Forum (2015) (167)
- Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon (1999) (160)
- Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial (2014) (146)
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. (2015) (145)
- Pyridorin in type 2 diabetic nephropathy. (2012) (141)
- T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. (1999) (141)
- Natural History of Cardiovascular Disease in Patients With Diabetes (2008) (140)
- Personalized Management of Hyperglycemia in Type 2 Diabetes (2013) (139)
- Glycemic Effects of Moderate Alcohol Intake Among Patients With Type 2 Diabetes (2007) (136)
- Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients (2005) (136)
- Reproducibility of glucose measurements using the glucose sensor. (2002) (132)
- Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. (2012) (129)
- Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus (2020) (127)
- Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. (2004) (125)
- Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? (2014) (125)
- Basal-State Hyperinsulinemia in Healthy Normoglycemic Adults Is Predictive of Type 2 Diabetes Over a 24-Year Follow-Up (2009) (125)
- Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. (2001) (124)
- Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. (2005) (121)
- New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies (2004) (121)
- Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. (2011) (117)
- Cannabidiol arrests onset of autoimmune diabetes in NOD mice (2008) (117)
- Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. (2002) (116)
- Treatment of new‐onset type 1 diabetes with peptide DiaPep277® is safe and associated with preserved beta‐cell function: extension of a randomized, double‐blind, phase II trial (2007) (115)
- The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial (2018) (112)
- Abnormal Regulation of Protein Tyrosine Phosphatase Activities in Skeletal Muscle of Insulin-Resistant Humans (1991) (111)
- The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach (2010) (110)
- Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum (2016) (109)
- Therapy in the Early Stage: Incretins (2011) (108)
- Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. (2007) (106)
- The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. (2011) (102)
- Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes (2019) (102)
- DECLARE‐TIMI 58: Participants’ baseline characteristics (2018) (101)
- Maggot therapy for the treatment of diabetic foot ulcers. (1998) (99)
- Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial (2017) (95)
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes (2008) (91)
- Influence of Small-Group Education Sessions on Glucose Homeostasis in NIDDM (1988) (86)
- Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes (2016) (85)
- Noninvasive continuous glucose monitoring using photoacoustic technology-results from the first 62 subjects. (2007) (83)
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text (2007) (82)
- Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. (2019) (80)
- Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial (2017) (78)
- Renal nitric oxide production during the early phase of experimental diabetes mellitus. (2000) (77)
- Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. (2016) (76)
- Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs (2011) (74)
- Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia (2011) (74)
- Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial (2015) (69)
- Moderate exercise improves glucose metabolism in uncontrolled elderly patients with non-insulin-dependent diabetes mellitus. (1994) (69)
- Diabetes: mellitus or lipidus? (2003) (68)
- Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease (2018) (67)
- Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies (2005) (67)
- Epinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle. (1991) (66)
- Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. (2008) (66)
- Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. (2009) (65)
- Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin (2014) (64)
- Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management (2014) (63)
- Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. (2009) (63)
- Present and Future: Pharmacologic Treatment of Obesity (2011) (63)
- Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study (2019) (62)
- Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes (2013) (61)
- Adolescent Obesity and Early-Onset Type 2 Diabetes (2020) (59)
- Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L). (2018) (58)
- Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. (2008) (57)
- Haemoglobin A1c is a predictor of COVID‐19 severity in patients with diabetes (2020) (55)
- Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial (2013) (54)
- Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes (2004) (54)
- Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial (2015) (53)
- The emerging role of VEGF in diabetic kidney disease. (2003) (52)
- Impaired Glucose-Stimulated Insulin Secretion Is Coupled With Exocrine Pancreatic Lesions in the Cohen Diabetic Rat (2008) (51)
- Lipotoxicity versus adipotoxicity—The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes (2006) (51)
- Effects of moderate intensity glycemic control after cardiac surgery. (2010) (51)
- CD44 Involvement in Autoimmune Inflammations (2007) (51)
- Immune modulation for prevention of type 1 diabetes mellitus. (2005) (50)
- Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial (2014) (50)
- Increased Expression of Endothelin-Converting Enzyme-1c Isoform in Response to High Glucose Levels in Endothelial Cells (2004) (50)
- Vitamins and trace metals status in non insulin dependent diabetes mellitus. (1991) (48)
- Improvement in Glucose Control in Difficult-to-Control Patients With Diabetes Using a Novel Flash Glucose Monitoring Device (2016) (48)
- The Role of Sulodexide in the Treatment of Diabetic Nephropathy (2012) (48)
- Endocrinology: Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups (1995) (48)
- Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists (2015) (48)
- Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement (2009) (47)
- Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial (2019) (46)
- Insulin-like growth factor-1 (IGF-1) enhances recovery from HgCl2-induced acute renal failure: the effects on renal IGF-1, IGF-1 receptor, and IGF-binding protein-1 mRNA. (1995) (45)
- LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial (2016) (45)
- Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results (2009) (45)
- An update on DPP-4 inhibitors in the management of type 2 diabetes (2016) (44)
- Effect of Moderate Exercise on Serum Lipids in Young Men with Low High Density Lipoprotein Cholesterol (1988) (44)
- The effect of a low carbohydrate energy-unrestricted diet on weight loss in obese type 2 diabetes patients – A randomized controlled trial (2011) (43)
- Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs (2013) (43)
- Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes (2016) (42)
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. (2008) (42)
- Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. (2008) (41)
- Digital therapy in diabetes (2017) (41)
- Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". (2015) (41)
- Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies? (1996) (40)
- Predicting the 20‐year diabetes incidence rate (2007) (40)
- Basal state hyperinsulinemia in healthy normoglycemic adults heralds dysglycemia after more than two decades of follow up (2012) (39)
- Dose-response relationship of oral insulin spray in healthy subjects. (2005) (39)
- Time course of lipopolysaccharide-induced nitric oxide synthase mRNA expression in rat glomeruli. (1999) (39)
- Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk (2018) (39)
- Oral administration of insulin in solid form to nondiabetic and diabetic dogs. (1994) (38)
- Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. (2004) (38)
- High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. (2005) (38)
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. (2019) (38)
- Differences in mtDNA haplogroup distribution among 3 Jewish populations alter susceptibility to T2DM complications (2008) (38)
- Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. (1996) (37)
- Defective insulin response of phosphorylase phosphatase in insulin-resistant humans. (1992) (37)
- The influence of zinc supplementation on glucose homeostasis in NIDDM. (1989) (36)
- Impact of treatment with saxagliptin on glycaemic stability and β‐cell function in the SAVOR‐TIMI 53 study (2015) (36)
- Diffuse Narrowing of Coronary Arteries in Diabetic Patients: The Earliest Phase of Coronary Artery Disease (1998) (36)
- American Diabetes Association Indications for Statins in Diabetes (2009) (36)
- Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. (2005) (36)
- Different effects of bariatric surgical procedures on dyslipidemia: a registry-based analysis. (2017) (35)
- Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials (2022) (35)
- Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hypoxic conditions. (1998) (35)
- Different contributions of insulin resistance and beta‐cell dysfunction in overweight Israeli Arabs with IFG and IGT (2006) (34)
- Prediction of progression from pre‐diabetes to diabetes: Development and validation of a machine learning model (2020) (34)
- Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. (2005) (33)
- DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL (2019) (31)
- Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58 (2020) (31)
- Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58 (2020) (30)
- Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. (2016) (30)
- Assessment of insulin resistance by a 13C glucose breath test: a new tool for early diagnosis and follow-up of high-risk patients (2010) (30)
- Role of protein kinase C in the expression of endothelin converting enzyme-1. (2009) (30)
- Role of Renal Nitric Oxide Synthase in Diabetic Kidney Disease during the Chronic Phase of Diabetes (2006) (30)
- Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial. (2019) (29)
- The Importance of Short‐Term Off‐Target Effects in Estimating the Long‐Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers (2014) (29)
- Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment (2012) (29)
- The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain. (2009) (29)
- Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin (2010) (28)
- Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. (2005) (28)
- Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. (2005) (28)
- Early Insulinization to Prevent Diabetes Progression (2013) (27)
- Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes (2017) (27)
- Benefits of a simple glycaemic protocol in an orthopaedic surgery ward: a randomized prospective study (2012) (27)
- Glucose tolerance factor extracted from yeast: oral insulin-mimetic and insulin-potentiating agent: in vivo and in vitro studies (2011) (27)
- Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts (2016) (27)
- Emerging gliptins for type 2 diabetes (2013) (26)
- Corrigendum to “Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes” [Diabetes Research and Clinical Practice 66 (2004) 193–201] (2006) (26)
- Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. (2006) (26)
- Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa (2020) (26)
- Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. (2003) (26)
- β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model (2014) (25)
- DiaPep277® Preserves Endogenous Insulin Production by Immunomodulation in Type 1 Diabetes (2006) (25)
- Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58 (2020) (25)
- 40th EASD Annual Meeting of the European Association for the Study of Diabetes (2004) (25)
- Assessing the levels of immunoglobulins in the saliva of diabetic individuals with periodontitis using checkerboard immunodetection. (2007) (25)
- Hyperglycemia induces accumulation of glucose in human skeletal muscle. (1991) (25)
- Disparate effects of exercise training on glucose tolerance and insulin levels and on ambulatory blood pressure in hypertensive patients (1993) (24)
- The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 (2021) (24)
- Trace elements in blood cells of diabetic subjects. (1989) (24)
- Frequency of cancer events with saxagliptin in the SAVOR‐TIMI 53 trial (2016) (24)
- Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction (2019) (24)
- The emerging role of NO and IGF‐1 in early renal hypertrophy in STZ‐induced diabetic rats (2011) (23)
- Reduced negative surface charge on arterial endothelium of diabetic rats (1988) (23)
- Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. (1985) (23)
- Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. (2020) (23)
- The role of insulin pump therapy for type 2 diabetes mellitus (2017) (23)
- Dietary copper supplementation restores β-cell function of Cohen diabetic rats: a link between mitochondrial function and glucose-stimulated insulin secretion. (2013) (22)
- Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). (2019) (22)
- Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus (2012) (22)
- Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats. (1998) (22)
- Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes (2018) (21)
- Prevention of type 1 diabetes: today and tomorrow (2010) (21)
- Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. (2021) (21)
- The use of continuous insulin delivery systems in severely insulin-resistant patients. (2001) (21)
- PRECLINICAL EVALUATION OF PHARMACOKINETIC PHARMACOKINETIC PHARMACODYNAMIC RATIONALE FOR ORAL CR METFORMIN FORMULATION (2001) (21)
- Activation of skeletal muscle casein kinase II by insulin is not diminished in subjects with insulin resistance. (1991) (21)
- Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities. (2003) (21)
- Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study (2020) (21)
- Diet and coronary heart disease in diabetes (2003) (21)
- Oral Administration of β-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial. (2017) (21)
- Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. (2017) (20)
- Epinephrine increases tricarboxylic acid cycle intermediates in human skeletal muscle. (1991) (20)
- Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study (2018) (20)
- A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans (1985) (20)
- Noninjectable methods of insulin administration. (2006) (20)
- From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes (2021) (20)
- Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization (2021) (19)
- Digital health technology and diabetes management (2018) (19)
- Diabetic foot disease is associated with reduced erythrocyte deformability (2016) (19)
- Influence of chronic diabetes on tissue and blood cells status of zinc, copper, and chromium in the rat. (1988) (19)
- Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial (2021) (19)
- Early use of insulin in type 2 diabetes. (2005) (18)
- Effect of short-term hyperglycemia on protein kinase C alpha activation in human erythrocytes. (2012) (18)
- Heart failure: SGLT2 inhibitors and heart failure — clinical implications (2016) (18)
- Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No (2009) (18)
- The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. (2015) (18)
- Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS (2016) (18)
- Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme (2015) (18)
- Prevalence of symptoms suggestive of gastroparesis in a cohort of patients with diabetes mellitus. (2013) (18)
- Insulin Therapy: Future Perspectives. (2019) (18)
- Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58 (2021) (18)
- Metabolic and genomic dissection of diabetes in the Cohen rat. (2007) (17)
- Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. (2003) (17)
- Altered tissue content of trace metals in diabetic hyperinsulinaemic sand rats (psammomys obesus) (1988) (17)
- Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back (2016) (17)
- Pharmacokinetics of valproic acid in volunteers after a single dose study. (1985) (17)
- Challenges in developing endpoints for type 1 diabetes intervention studies (2009) (17)
- Blood pressure and insulin in Ethiopian immigrants: longitudinal study. (1995) (16)
- Skeletal muscle glycogen synthase activity in subjects with non-insulin-dependent diabetes mellitus after glyburide therapy. (1990) (16)
- Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood (2019) (16)
- Blood pressure, glucose, insulin and lipids of young Ethiopian recent immigrants to Israel and in those resident for 2 years (1993) (16)
- Insulin-like growth factor-I (IGF-I) and IGF-I receptor gene expression in the kidney of the chronically hypoinsulinemic rat and hyperinsulinemic rat. (1995) (16)
- Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 Diabetes (2015) (16)
- Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. (2021) (16)
- Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel (2020) (16)
- Focus on childhood fitness, not just fatness (2006) (15)
- Pharmacokinetics: The Effect of the Mode of Administration on the Hypolipidaemic Activity of Niacin: Continuous Gastrointestinal Administration of Low‐dose Niacin Improves Lipid‐lowering Efficacy in Experimentally‐induced Hyperlipidaemic Rats (1998) (15)
- Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets (2021) (15)
- Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial (2020) (15)
- Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease (2017) (15)
- Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease. (2020) (14)
- Prediction of hypertension by the insulinogenic index in young Ethiopian immigrants (1995) (14)
- Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction. (2016) (14)
- Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat). (2003) (14)
- Octreotide, a Somatostatin Analogue, Fails to Inhibit Hypoxia-induced Retinal Neovascularization in the Neonatal Rat (2000) (14)
- Omega-loop gastric bypass is more effective for weight loss but negatively impacts liver enzymes: a registry-based comprehensive first-year analysis. (2017) (14)
- Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. (2021) (14)
- Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial. (2021) (13)
- In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatment (2007) (13)
- Effect of Mild Hypoinsulinemia on Renal Hypertrophy: Growth Hormone/Insulin-Like Growth Factor I System in Mild Streptozotocin Diabetes (2002) (13)
- Effect of acute N-nitro-L-arginine methyl ester (L-NAME) hypertension on glucose tolerance, insulin levels, and [3H]-deoxyglucose muscle uptake. (1997) (13)
- Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes. (2012) (13)
- Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal (2014) (13)
- Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms (2012) (13)
- Comparative pharmacokinetic evaluation of sustained-release theophylline formulations in dogs and humans (1987) (13)
- Obesity in late adolescence and incident type 1 diabetes in young adulthood (2022) (12)
- NAFLD in type 2 diabetes mellitus: Still many challenging questions (2020) (12)
- The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help? (2018) (12)
- Chronic exogenous hyperinsulinaemia without sugar supplementation: acute salt-sensitive hypertension without changes in resting blood pressure (1993) (12)
- Rapid activation of glycogen synthase and protein phosphatase in human skeletal muscle after isometric contraction requires an intact circulation (1995) (12)
- 244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial (2019) (12)
- Immigration to Israel during childhood is associated with diabetes at adolescence: a study of 2.7 million adolescents (2017) (12)
- Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. (2019) (12)
- Antidiabetic Effect of Interleukin-1β Antibody Therapy Through β-Cell Protection in the Cohen Diabetes-Sensitive Rat (2014) (12)
- Rectal administration of insulin. (1984) (12)
- Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in Psammomys obesus (2005) (11)
- Innovative Immune-Based Therapeutic Approaches for the Treatment of Type 1 Diabetes Mellitus (2005) (11)
- Prevalence of diabetes mellitus among workers in Israel:¶a nation-wide study (1999) (11)
- Insulin‐Induced Hypertension, l‐Arginine, and Endothelial Nitric Oxide Synthase in Pregnant Rats (2003) (11)
- Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial (2016) (11)
- Influence of moderate exercise on glucose homeostasis and serum testosterone in young men with low HDL-cholesterol level. (1988) (11)
- Differential effects on kidney and liver growth of a non-viral hGH-expression vector in hypophysectomized mice. (2007) (11)
- Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers (2004) (11)
- Metabolic syndrome and microangiopathy. (2006) (11)
- Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device (2014) (11)
- The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important? (2018) (10)
- Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID‐19: A retrospective, cohort study (2021) (10)
- Herbal flavonoids inhibit the development of autoimmune diabetes in NOD mice: proposed mechanisms of action in the example of PADMA 28 (2010) (10)
- INSULIN‐INDUCED RENAL DYSFUNCTION IN REGULAR SABRA RATS (1995) (10)
- IL-1β hampers glucose-stimulated insulin secretion in Cohen diabetic rat islets through mitochondrial cytochrome c oxidase inhibition by nitric oxide. (2014) (10)
- Abnormal regulation of ribosomal protein S6 kinase by insulin in skeletal muscle of insulin-resistant humans. (1993) (10)
- Nitrendipine improves glucose tolerance and deoxyglucose uptake in hypertensive rats. (1994) (9)
- Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes (2011) (9)
- Serum adiponectin is associated with homocysteine in elderly men and women, and with 5,10-methylenetetrahydrofolate reductase (MTHFR) in a sex-dependent manner. (2010) (9)
- The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus (2014) (9)
- Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. (2020) (9)
- Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement (2011) (9)
- Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. (1988) (9)
- The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus (2021) (9)
- Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes (2011) (8)
- The absorption of insulin: the absorption of insulin from the intestine in dogs (1989) (8)
- Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. (1984) (8)
- Saxagliptin for the treatment of diabetes - a focus on safety (2016) (7)
- Prevalence of glucose intolerance in young male Ethiopian immigrants. (1993) (7)
- Adolescent BMI and early-onset type 2 diabetes among Ethiopian immigrants and their descendants: a nationwide study (2020) (7)
- Relationship between Blood Glucose Control and Improved Cardiovascular Outcome after Stent Implantation in Diabetic Patients (2010) (7)
- Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease (2018) (7)
- Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. (1988) (7)
- Machine learning based study of longitudinal HbA1c trends and their association with all‐cause mortality: Analyses from a National Diabetes Registry (2021) (7)
- Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. (2022) (7)
- A combined approach to control valproic acid release via novel delivery system of valpromide: A kinetic and pharmacokinetic study (1986) (7)
- Hexokinase kinetics in human skeletal muscle after hyperinsulinaemia, hyperglycaemia and hyperepinephrinaemia. (1994) (7)
- Management of diabetic neuropathy. (2021) (6)
- Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies. (1987) (6)
- Gender-Specific Care of Diabetes (2007) (6)
- A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes (2021) (6)
- Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial (2020) (6)
- Validity of diagnostic codes and estimation of prevalence of diabetic foot ulcers using a large electronic medical record database (2018) (6)
- Diabetes epidemic and the thrifty gene. (2002) (6)
- Hypoglycaemia following pancreatic allograft transplantation. (1998) (6)
- Funding for practice-oriented clinical research (2006) (6)
- [The guidelines for the diagnosis prevention and treatment of type 2 diabetes mellitus--2005]. (2006) (6)
- For Debate Diabetes: mellitus or lipidus? (2003) (6)
- The endogenous insulin-like growth factor system in radiocontrast nephropathy. (1998) (6)
- Insulin Pump Therapy Versus Multiple Daily Injections in Obese Type 2 Diabetic Patients (2002) (6)
- Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real‐life clinical practice (2018) (6)
- Abstract 17503: Outcomes of Patients With Type 2 Diabetes and Known Congestive Heart Failure Treated With Saxagliptin: Analyses of the SAVOR-TIMI 53 Study (2013) (6)
- Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. (2022) (5)
- Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes (2015) (5)
- Diabetes therapy‐focus on Asia: second‐line therapy debate: insulin/secretagogues (2012) (5)
- Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508 (2014) (5)
- Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial. Diabetes Care 2014;37:1392–1400. DOI: 10.2337/dc13-1391 (2014) (5)
- Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials (2012) (5)
- 192Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58 (2019) (5)
- Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes (2016) (5)
- Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) (2021) (5)
- Complex impact of obesity on type 2 diabetes. (2005) (5)
- Adolescent Thyroid disorders and Risk for Type 2 Diabetes in Young Adulthood. (2021) (5)
- Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial (2006) (5)
- A polygenic risk score predicts atrial fibrillation in cardiovascular disease. (2022) (5)
- The relationship between inpatient hyperglycaemia and mortality is modified by baseline glycaemic status (2020) (5)
- Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. (2020) (5)
- Effect of saxagliptin on renal outcome (2014) (5)
- Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022) (5)
- Managing labor and delivery of the diabetic mother (2009) (4)
- Glucose Management by Registered Nurses for Adult Patients Hospitalized in Medical Wards: Structured Guidelines (Protocol) and Working Process (2010) (4)
- Improved Insulin Absorption by Means of Standardized Injection Site Modulation Results in a Safer and More Efficient Prandial Insulin TreatmentA Review of the Existing Clinical Data (2014) (4)
- Use of a Machine Learning Algorithm Improves Prediction of Progression to Diabetes (2018) (4)
- Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study (2017) (4)
- Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) (2013) (4)
- The effect of low dose octreotide administration on renal function and on gene expression of IGF-I axis components in experimental diabetes mellitus. (1998) (4)
- SGLT-2 inhibitors for people with type 2 diabetes – Authors' reply (2019) (4)
- The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus (2004) (4)
- An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes (2019) (4)
- Noninjectable methods of insulin administration. (2006) (4)
- SGLT2 inhibitors for primary prevention of cardiovascular events (2019) (4)
- Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial". (2019) (4)
- Safety and Efficacy of a Novel Extended Release Formulation of Metformin in Patients with Type 2 Diabetes (2000) (4)
- The Individualized Target HbA 1 c : A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain (2009) (4)
- The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease? (2019) (4)
- Insulin Therapy and Hypoglycemia - Present and Future (2011) (3)
- Stuttering and incident type 2 diabetes: a population-based study of 2.2 million adolescents. (2021) (3)
- Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201 (2017) (3)
- Lipids and glucose in type 2 diabetes: what about the beta-cell and the mitochondria?: response to Boden and Laakso. (2005) (3)
- Intervention of the Flash Glucose Sensing Technology on Glycemic Control and Treatment Satisfaction in Patients with Type 2 Diabetes Treated Intensively by Insulin—A Randomized Controlled Trial (2018) (3)
- PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL (2014) (3)
- Cytochrome c Oxidase Activity as a Metabolic Regulator in Pancreatic Beta-Cells (2022) (3)
- Abstract 16764: Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus and Heart Failure or Kidney Dysfunction - Observations From the SAVOR-TIMI 53 Trial (2016) (3)
- Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial (2022) (3)
- CHRONIC EXOGENOUS HYPERINSULINAEMIA ACCELERATES THE DEVELOPMENT OF HYPERTENSION IN SPONTANEOUSLY HYPERTENSIVE RATS (1995) (3)
- EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL (2020) (3)
- Monday, 27 August 2012 (2012) (3)
- Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) (2016) (3)
- Comment on Oosterwijk et al. High-Normal Protein Intake Is Not Associated With Faster Renal Function Deterioration in Patients With Type 2 Diabetes: A Prospective Analysis in the DIALECT Cohort. Diabetes Care 2022;45:35–41 (2022) (3)
- Digital Diabetes Care System Observations from a Pilot Evaluation Study in Vietnam (2020) (3)
- Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145–e146 (2016) (2)
- Tackling obesity during the COVID‐19 pandemic (2020) (2)
- Association of hyperglycemia and insulin with diabetic cardiovascular complications. (2003) (2)
- Establishing priorities for diabetes action goals according to key opinion leaders and health professionals (2022) (2)
- Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans (2004) (2)
- Adolescent cognitive function and incident early-onset type 2 diabetes (2021) (2)
- Insulin-like growth factors (IGFs) and IGF-binding proteins in diabetic kidney disease. (1995) (2)
- Comparison of glucose tolerance, lipids and blood pressure in young male Ethiopians from two different immigrations, 1989 and 1991. (1993) (2)
- Comparison of HBA1c Goals Proposed by an Algorithm To Those Set By Different Members of Healthcare Teams Within the Dartmouth Hitchcock Health System. (2018) (2)
- Autotomy is prevented by hyperglycemia and reduced by consuming sweet solutions (1987) (2)
- Abstract 15035: Liraglutide Reduces Major Cardiovascular Events in Patients With Chronic Kidney Disease: Results From the Leader Trial (2017) (2)
- Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease. (2021) (2)
- Myopia and Early Onset Type 2 Diabetes: A Nationwide Cohort Study. (2021) (2)
- Exogenous hyperinsulinemia and atherosclerosis in type 1 diabetic patients. (2013) (2)
- Analysis: Accuracy Performance of the Medtronic NexSensor for 6 Days in an Inpatient Setting Using Abdomen and Buttocks Insertion Sites (2011) (2)
- Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial". (2020) (2)
- Letter Regarding Normal Albuminuria in Patients With Autopsy-Proven Advanced Diabetic Nephropathy (2022) (2)
- Atrophy or hypertrophy in chronic renal ischemia: role of the IGF-I system. (2001) (2)
- Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58 (2019) (2)
- Blood pressure measurement method not responsible for results of Brands et al. (1994) (2)
- RISK STRATIFICATION WITH THE TIMI RISK SCORE FOR SECONDARY PREVENTION AMONG PATIENTS WITH DIABETES AND ELEVATED CARDIOVASCULAR RISK (2017) (2)
- Effect of a primary-care-team focused diabetes educational program project on diabetes care quality indicators in a large health maintenance organization. (2021) (2)
- Asthma in Youth and Early-Onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. (2021) (2)
- Diabetic Proteinuria Revisited: Updated Physiologic Perspectives (2022) (2)
- [Sodium glucose co-transporter 2 inhibitors in heart failure therapy]. (2020) (2)
- Global Call for Free Academic Movement for International Dialogue (2012) (2)
- Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) (2011) (1)
- Interventions in diabetic patients after myocardial infarction (2003) (1)
- Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes (2013) (1)
- NATRIURETIC PEPTIDES VERSUS A CLINICAL HISTORY OF HEART FAILURE FOR RISK PREDICTION IN PATIENTS WITH DIABETES (2019) (1)
- Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data (2022) (1)
- Five years into the Israeli National Diabetes Program – are we on the right track? (2020) (1)
- Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics (2019) (1)
- Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal. Diabetes Care 2014;37:1384–1391. DOI: 10.2337/dc13-1392 (2014) (1)
- Thiazolidinediones in Cardiovascular Risk in Type 2 Diabetes Mellitus (2003) (1)
- The Controversies in Obesity, Diabetes and Hypertension (CODHy) Meeting (2008) (1)
- Bethanechol-Induced Cholinergic Toxicity in Diabetic Neuropathy (1990) (1)
- Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study. (2023) (1)
- Correction to: Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study (2018) (1)
- Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes (2013) (1)
- Abstract 15581: Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial (2019) (1)
- 1263-P: Adolescent Obesity and Incident Type 1 Diabetes in Young Adulthood (2022) (1)
- Continuous subcutaneous insulin infusion—an opportunity for better care but not a “magic pill” (2017) (1)
- Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58 (2020) (1)
- Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58 (2020) (1)
- Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. (2023) (1)
- MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58 (2021) (1)
- In anticipation of patient participation. (2009) (1)
- Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: how low can we go? (2010) (1)
- Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) (2009) (1)
- Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease (2020) (1)
- The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue. (2011) (1)
- Glycemic Targets and Prevention of Chronic Complications (2018) (1)
- Pharmacokinetic analysis of valdice — a diethylcarbonate prodrug of valproic acid (1994) (1)
- Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. (2022) (1)
- Acute dysphasia associated with hypoglycemia. (1984) (1)
- CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL (2016) (1)
- 1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58 (2020) (1)
- Author’s reply (2003) (0)
- New treatments for diabetes. (2007) (0)
- Acarbose in the Treatment of NIDDM Patients with Hyperlipidemia (1988) (0)
- Insulin resistance associated with lower rates of weight gain in Pima (2017) (0)
- 303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial (2020) (0)
- Serum from type 2 diabetes patients consuming a three-meal diet resets circadian rhythms in cultured hepatocytes. (2021) (0)
- Practical Approach to the Implementation of Diabetes Prevention (2013) (0)
- Improved pharmacokinetic and pharmacodynamic profile of insulin analogs using InsuPatch , a local heating device Running Title : Local heating device and insulin action (2014) (0)
- Sitagliptin Review of its Use in the Management of Type 2 (2010) (0)
- GENETIC PREDISPOSITION TO ADIPOSITY IS ASSOCIATED WITH GREATER RISK OF SUBSEQUENT HEART FAILURE EVENTS IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS (2023) (0)
- 410Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus (2019) (0)
- 788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58 (2021) (0)
- Feasibility of Creating a Diagnosis-Based Diabetic Foot Registry in a Large Health Care Provider (2018) (0)
- PATTERNS OF ASPIRIN UTILIZATION AND OUTCOMES AMONG PATIENTS WITH DIABETES MELLITUS: A PROPENSITY SCORE MATCHED ANALYSIS FROM THE SAVOR-TIMI 53 TRIAL (2016) (0)
- 236-OR: Effects of Dapagliflozin on Progression of Diabetic Kidney Disease: Analysis from DECLARE-TIMI 58 Trial (2019) (0)
- Subject Index Vol. 102, 2006 (2006) (0)
- RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58 (2023) (0)
- Biomedical research in Israel: does it have a future? (2000) (0)
- Adolescent NAFLD & Type 2 Diabetes- Supplementary Material.docx (2020) (0)
- PERFORMANCE OF A NOVEL GENETIC RISK SCORE TO IDENTIFY RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CARDIOMETABOLIC DISEASE (2020) (0)
- Contents, Vol. 71, 1984 (1984) (0)
- Longitudinal observations on blood pressure, glucose, insulin and lipid levels in ethiopian immigrants (1995) (0)
- BASELINE RENAL FUNCTION AND CARDIOVASCULAR RISK IN PATIENTS TREATED WITH SAXAGLIPTIN: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL (2014) (0)
- A cc ep te d A rti cl e Digital therapy in diabetes Running title : Digital therapy in diabetes (2017) (0)
- K009: Insulin-like growth factor-1 (IGF-1) levels determine atrophy or hypertrophy in chronic renal ischemia (2000) (0)
- [THE CHALLENGE OF HEALTHY AGING WITH DIABETES: THE ISRAELI NATIONAL DIABETES COUNCIL GUIDELINES FOR TREATING OLDER PEOPLE]. (2021) (0)
- Response to: ‘baseline differences in SAVOR trial’ – prespecified vs. post hoc analysis – a potential source of bias (2015) (0)
- Characterizing Hypoglycemic Events during Saxagliptin Treatment in Type 2 Diabetes (2014) (0)
- Editor's foreword (1988) (0)
- Proposing a new design for self‐monitoring blood glucose logs (2016) (0)
- Author response for "Pre‐infection glycaemic control and disease severity among patients with type 2 diabetes and COVID ‐19: A retrospective, cohort study" (2021) (0)
- [Diabetic ketoacidosis--beware of cerebral edema!]. (2007) (0)
- Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study (2023) (0)
- Editor's Foreword (2001) (0)
- Maintenance of ambulatory diabetic patients on subcutaneous insulin pump. (1984) (0)
- RF28 | PSUN302 Obesity at Late Adolescence and Incident Type 1 Diabetes in Young Adulthood (2022) (0)
- blood flow during local heating Nitric oxide and neurally mediated regulation of skin (2015) (0)
- The Association between Inpatient Hyperglycemia and Thirty-Day Mortality Is Modified by Type 2 Diabetes History (2018) (0)
- Review for "Insulin Secretion is a Strong Predictor for Need of Insulin Therapy in Patients With New Onset Diabetes and HbA1c >10%, a post hoc analysis of EDICT study" (2021) (0)
- Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. (2022) (0)
- [NATIONAL DIABETES PROGRAM IN ISRAEL AND IN SELECTED COUNTRIES - CURRENT STATE AND FUTURE TRENDS]. (2021) (0)
- [778] AMELIORATION OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND THE METABOLIC SYNDROME IN DIABETIC COHEN RATS IS ASSOCIATED WITH REDUCED PANCREATIC INJURY (2007) (0)
- DIAPEP277^ PRESERVES ENDOGENOUS INSULIN BY IMMUNOMODULATION IN TYPE 1 DIABETES (T1D) PATIENTS (2005) (0)
- Abstract 10083: The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial (2019) (0)
- Diabetic retinopathy screening in the emerging era of artificial intelligence Jakob Grauslund Using screening for the early detection of sight-threatening diabetic retinopathy is a pivotal step towards the reduction (2022) (0)
- Subject Index, Vol. 71, 1984 (1984) (0)
- BLOOD PRESSURE, SUBCLINICAL MYOCARDIAL INJURY AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH DIABETES AND HIGH CARDIOVASCULAR RISK: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL (2017) (0)
- Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 (2022) (0)
- Prolonged response to glibenclamide in NIDDM patients in a normoglycemic state. (1994) (0)
- GI262570, a non-thiazolidinedione, tyrosine-based PPARγ agonist improves overall metabolic control in combination with glibenclamide (2000) (0)
- Components of the diets provided in the study ’ s metabolic component (2007) (0)
- Cardiovascular complications in diabetic patients (2011) (0)
- Response to Mastrototaro and Gross (2003) (0)
- Efficacy and tolerance of insulin degludec administered once/day in a pattern unique flexible compared to insulin glargine once daily at a fixed time in patients with type 2 diabetes (T2D) (2012) (0)
- Curalin supplement for patients with type 2 diabetes mellitus (2023) (0)
- Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. (2023) (0)
- Human Antibodies & Hybridomas November (2013) (0)
- [New insight into old disease: potential treatment of type 2 diabetes mellitus by bariatric surgery]. (2010) (0)
- Creating Individualized HBA1C Targets Using Predictive Modeling (2017) (0)
- Retraction Note: Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis’ (2015) (0)
- FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58 (2022) (0)
- Exocrine Insufficiency in Transplanted Pancreas Imitating Pancreatic Rejection (1994) (0)
- PL-218: The weight loss or the procedure? Effect of different bariatric operations on hyperlipidemia (2009) (0)
- Gender-specific treatment of the diabetic patient: Can we minimize risk factors in fetal programming? (2006) (0)
- ASSESSMENT OF ATHEROTHROMBOTIC RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (2022) (0)
- Vaccination studies in type 1 diabetes. Authors' reply (2002) (0)
- Endothelial Dysfunction in Diabetes: The Role of Protein Kinase C (2008) (0)
- Primary prevention of type 2 diabetes: how do we do it? (2004) (0)
- Reply to the letter of Draves et al. In response to the article: "Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization" (Kesavadev et al.)". (2021) (0)
- MMC celebrating 6 years of experience and expansion (2022) (0)
- ia ls Diabetes Epidemic and the Thrifty Gene (2002) (0)
- [HEMOGLOBIN A1C AND MORTALITY FROM COVID-19]. (2021) (0)
- Randomized Trial Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 (2014) (0)
- Type 2 Diabetics, insulin degludec administered once/daily according to a flexible schema assured glycemic control similar to a daily administration according to a fixed hour schema without augmenting hypoglycemic episods (2012) (0)
- [Surgical treatment of morbid obesity]. (2008) (0)
- ResearchAssessment of insulin resistance by a 13 C glucose breath test : a new tool for early diagnosis and follow-up of high-risk patients (2015) (0)
- Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial (2020) (0)
- Issue Information (2019) (0)
- Abstract 17270: Outcomes of Patients With Type 2 Diabetes at High Risk of Cardiovascular Events Treated With Saxagliptin: Outcomes by Baseline HgbA1c (2013) (0)
- Prevention of Diabetes in Israel (2014) (0)
- Efficacy and safety of dapagliflozin according to baseline blood pressure – observations from DECLARE-TIMI 58 Trlial (2020) (0)
- The endogenous insulin-like growth factor system in radiocontrast nephropathy. (1998) (0)
- 9 Insulin Therapy and Hypoglycemia-Present and Future (2017) (0)
- [DIABETES - PRESENT AND FUTURE]. (2021) (0)
- Are we overtreating cardiovascular disease in diabetic patients (2013) (0)
- Sitagliptin: a viewpoint by Itamar Raz. (2007) (0)
- RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (2023) (0)
- Myocardial changes in streptozotocin induced diatetic rats: morphometry in isolated perfused hearts (1993) (0)
- [COMPARISON OF A RECOMMENDATION FOR A DESIRABLE HBA1C VALUE BY INTERNAL WARD PHYSICIANS, DIABETES PHYSICIANS AND AN APPLICATION, FOR DIABETES PATIENTS DISCHARGED FROM HOSPITALIZATION IN AN INTERNAL WARD]. (2021) (0)
- Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials (2022) (0)
- Characterization of Differentially Expressed Protein Biomarkers in Pancreatic Tissues Derived from the Cohen Diabetic Rat Model of Type 2 Diabetes (2007) (0)
- Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects. (1985) (0)
- Vaccination studies in type 1 diabetes (2002) (0)
- DiaPep277(R) Shows Promise as a Therapeutic Strategy for Type 1 Diabetes (2012) (0)
- [Primary care for type 2 diabetes]. (2004) (0)
- INFLAMMATORY AND CARDIAC BIOMARKERS ARE ASSOCIATED WITH RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM SAVOR-TIMI 53 (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Itamar Raz?
Itamar Raz is affiliated with the following schools: